The publications on this site are part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726

Skip to Page Content

Full Deal Summary

Oncology start-up Harpoon Therapeutics raised $45mm through its Series B round. Arix Bioscience and New Leaf Ventures co-led, and were joined by additional investor Taiho Ventures and returning backer MPM Capital. Arix and New Leaf have joined Harpoon’s board of directors, and Taiho’s president will be on the board as an observer.

Harpoon was formed in 2015 by MPM Capital (which reportedly provided a $15mm Series A round to the company) and T-cell researcher Patrick Baeuerle, PhD, and is developing cancer therapies based on its TriTAC (Tri-specific T cell Activating Construct) platform. TriTAC antibodies bind simultaneously to cancer cells and a patient’s own T-cells, causing the T-cells to release toxins that destroy the tumor. Harpoon’s lead candidate HPN424 is a prostate-specific membrane antigen-targeting TriTAC for metastatic prostate cancer. The company will use the Series B proceeds to advance HPN424 and another lead project into Phase I trials.

+ Show All | – Hide All


Click a figure for comparable deals.

Potential Deal Value $45.00mm
Transactions 1 of 1 (05/2017)
Round # 2
Funding Stage Additional Round
Equity $45.00mm
Total Line Value $45.00mm
Gross Proceeds $45.00mm
Investors Arix Bioscience PLC
MPM Capital
New Leaf Venture Partners
Taiho Ventures

Deal Information

Click a keyword for comparable deals.

Deal Industry Biotechnology
Large Molecule
Deal Status Final
Deal Type Financing
Private Placement

Company Information

Click a keyword for comparable companies.

Harpoon Therapeutics Inc.
View Company Profile | View Company Deals
Company Location Worldwide
North America
Industry Biotechnology
Large Molecule
Description Start-Up
Ownership Private
Therapeutic Area(s) of Focus Cancer